Sinn Fein ‘ignored role of 3,000 deaths in damaging community relations’SACRAMENTO, Calif. (AP) — Marquel Sutton scored 23 points as Omaha beat Sacramento State 70-60 on Saturday night. Sutton added eight rebounds for the Mavericks (4-7). Tony Osburn scored 15 points and added five rebounds and three steals. JJ White had nine points and went 4 of 5 from the field. Jacob Holt led the way for the Hornets (2-7) with 15 points, six rebounds and two blocks. Mike Wilson added nine points and six rebounds for Sacramento State. Chudi Dioramma had seven points, 10 rebounds and two blocks. Omaha's next game is Friday against Northern Iowa on the road, and Sacramento State hosts UC Davis on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for WHO group 1 pulmonary hypertension (PH, or PAH) over the course of one week in March, one treatment appears to have had a more successful launch than the other. Sotatercept uptake "has been rapid and, I believe, even better than projected," said Kristin Highland, MD, a pulmonologist at the Cleveland Clinic. In contrast, "the uptake of Opsynvi has been slow due to restrictions by payors given the availability of generic [single-agent] formulations and cumbersome prior-authorization and patient assistance programs for PAH medications as a whole, making the desire to go through yet another prior-approval process less appealing for patients already on therapy," observed Highland. However, the landscape of PAH therapy is still evolving, and the roles these drugs play in clinical practice may change as more data are generated. Sotatercept A flurry of excitement has surrounded sotatercept since the release of findings from its phase II PULSAR trial. Its approval this year as the first activin-signaling inhibitor for PAH -- indicated to increase exercise capacity, improve functional class, and reduce the risk of clinical worsening events for eligible adults -- was viewed as opening a new chapter for people with the rare progressive disorder typically associated with high morbidity and mortality. The case for sotatercept was also recently strengthened by topline results of the ZENITH trial, announced by Merck in late November, which found that sotatercept reduced the risk of morbidity or mortality events atop background PAH therapy in the sickest patients. The initial results were strong enough for the... Nicole LouSutton scores 23, Omaha knocks off Sacramento State 70-60
MOREHEAD, Ky. (AP) — Isaiah Smith ran for a career-high 205 yards on 31 carries and scored a touchdown and San Diego beat Morehead State 37-14 in a season-ending contest for both teams on Saturday. Grant Sergent threw for 184 yards and two touchdowns for San Diego (8-3, 6-2 Pioneer Football League) which ended the season with a four-game win streak and winners of six of seven.Star-studded evening featured Tamron Hall , Halsey, and Honored LRA Founder Robert Wood Johnson and Verizon Chairman and CEO Hans Vestberg NEW YORK , Nov. 26, 2024 /PRNewswire/ -- The 2024 Lupus Research Alliance (LRA) Breaking Through Gala raised nearly $3 million for lupus research, bringing the hope for a world free of lupus closer with every dollar. Emceed by two-time Emmy Award-Winning host and bestselling author Tamron Hall , the evening included a commanding performance by GRAMMY ® nominated genre-blending singer, songwriter, and activist Halsey . In welcoming the 500 guests, Tamron Hall explained why she continues to support the Lupus Research Alliance. "Almost everyone in this room knows what it means to live with lupus only too well – you cope with it every day, or you see its effects on someone you love – and sometimes that's even harder to bear," Hall commented. "I too watch several people I am close to struggle with this disease. Like you, I am here tonight, helping increase disease awareness and raise funds for the most promising research because that is how we can best help the people we care so much about." This spring, Halsey bravely revealed her lupus diagnosis, raising broad public awareness among 30+ million Instagram followers and beyond, referring them to the Lupus Research Alliance to learn more. On the heels of releasing a powerful album about struggling with chronic illness, including lupus, Halsey shared her lupus journey with Gala guests before performing. "Opening up about my own lupus diagnosis a few months ago has brought me a sense of comfort, knowing I'm now part of such a passionate and supportive community," said Halsey. "I hope that through my music, I can help amplify the strength we all share and the brighter future we're working toward." LRA President and CEO Albert T. Roy commented, "This year's Gala celebrates the Heart of Innovation – inspiring words that eloquently convey why so many support the work of the LRA. Our organization was founded and continues to be fueled by people like this year's co-honorees The Honorable Robert Wood Johnson and Verizon Chairman and CEO Hans Vestberg who believe in the power of science and technology as the best way to help those living with lupus. Our mission is driven by that kind of passion, getting to the very heart of what causes lupus and bringing forth innovative discoveries that are transforming lives." Why improved treatments are still so urgently needed was poignantly illustrated by speaker Jenny Zwick along with her husband and Board member Spencer sharing how lupus has affected their lives. Special Supporters Recognized for Contributions Mr. Roy also thanked Lady Gaga and Selena Gomez for their support as Gala Honorary Co-Chairs along with the event Co-Chairs: Ira Akselrad, President of The Johnson Company and Lupus Research Alliance Board Chair; Bob Pittman , Chairman and CEO of iHeartMedia, Inc.; and Spencer J. Zwick ; Co-Founder and Managing Partner of Solamere Capital. Philanthropist and Honorary Gala Co-Chair Michael R. Bloomberg addressed the audience in a special videotaped message of enduring support for the lupus cause as well as a tribute to the organization's late Board of Directors Co-Chair Richard K. DeScherer who passed away this past year. Robert Wood Johnson Honored for Founding the LRA to Improve the Future for Daughter Jaime LRA Founding Chairman The Honorable Robert Wood Johnson started the Lupus Research Alliance (then the Alliance for Lupus Research) in 1999 to find answers when his daughter was first diagnosed with lupus as a young child. Ambassador Johnson explained, "Back then, there was not even one treatment developed for lupus and few scientists were working in the field. Funding more research to improve treatment was clearly critical, not just for my daughter, but for millions more. I am proud that our work laid the foundation for two of the three current lupus-specific treatments, and for many more now in clinical development." Honoree Hans Vestberg Recognized for Verizon Support of Lupus Research As Chairman and CEO of Verizon, Hans Vestberg was also honored for the company's long-standing commitment to furthering lupus research. In addition to many years supporting the LRA Walk program directly, Verizon is a cornerstone sponsor of the New York Jets, contributing to the Jets Foundation which is committed to the LRA as one of its primary causes. In addition to thanking the speakers on stage, Mr. Roy also applauded the entire lupus community who donate for LRA-funded research, advocate for federal research funding, raise disease awareness and participate in clinical research – all doing what they can to improve current treatment and ultimately free the world of lupus. He also pointed everyone's attention to the lighting of the iconic Empire State Building which lit up NYC's skyline in the colors of lupus research – purple and red. About Lupus Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. In lupus, the immune system, meant to defend against infections, produces autoantibodies that mistake the body's own cells as foreign, causing other immune cells to attack organs such as the kidneys, brain, heart, lungs and skin, as well as blood and joints. Ninety percent of people with lupus are women, most often diagnosed between the ages of 15-45. Black, Latinx, Indigenous, Asian and Pacific Islander people are disproportionately affected by lupus and more likely to experience severe lupus symptoms. About the Lupus Research Alliance The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs. For more information or to donate to lupus research, visit the LRA at LupusResearch.org and on social media at: X , Facebook , LinkedIn , and Instagram . View original content to download multimedia: https://www.prnewswire.com/news-releases/2024-lupus-research-alliance-gala-raises-millions-to-improve-lives-of-people-with-lupus-302316842.html SOURCE Lupus Research Alliance
Extensive confidential documents in the lead-up to the collapse of Northern Ireland’s institutions in 2002 have been made available to the public as part of annual releases from the Irish National Archives. They reveal that the Irish Government wanted to appeal to the UK side against “manipulating” every scenario for favourable election results in Northern Ireland, in an effort to protect the peace process. In the years after the landmark 1998 Good Friday Agreement, a number of outstanding issues left the political environment fraught with tension and disagreement. Mr Trimble, who won a Nobel Peace Prize with SDLP leader John Hume for their work on the Agreement, was keen to gain wins for the UUP on policing, ceasefire audits and paramilitary disarmament – but also to present his party as firmer on these matters amid swipes from its Unionist rival, the DUP. These issues were at the front of his mind as he tried to steer his party into Assembly elections planned for May 2003 and continue in his role as the Executive’s first minister despite increasing political pressure. The documents reveal the extent to which the British and Irish Governments were trying to delicately resolve the contentious negotiations, conscious that moves seen as concessions to one group could provoke anger on the other side. In June 2002, representatives of the SDLP reported to Irish officials on a recent meeting between Mr Hume’s successor Mark Durkan and Prime Minister Tony Blair on policing and security. Mr Blair is said to have suggested that the SDLP and UUP were among those who both supported and took responsibility for the Good Friday Agreement. The confidential report of the meeting says that Mr Durkan, the deputy First Minister, was not sure that Mr Trimble had been correctly categorised. The Prime Minister asked if the SDLP could work more closely with the UUP ahead of the elections. Mr Durkan argued that Mr Trimble was not only not saleable to nationalists, but also not saleable to half of the UUP – to which Mr Blair and Northern Ireland Secretary John Reid are said to have laughed in agreement. The SDLP leader further warned that pursuing a “save David” campaign would ruin all they had worked for. Damien McAteer, an adviser for the SDLP, was recorded as briefing Irish officials on September 10 that it was his view that Mr Trimble was intent on collapsing the institutions in 2003 over expected fallout for Sinn Fein in the wake of the Colombia Three trial, where men linked to the party were charged with training Farc rebels – but predicted the UUP leader would be “in the toilet” by January, when an Ulster Unionist Council (UUC) meeting was due to take place. A week later in mid September, Mr Trimble assured Irish premier Bertie Ahern that the next UUC meeting to take place in two days’ time would be “okay but not great” and insisted he was not planning to play any “big game”. It was at that meeting that he made the bombshell announcement that the UUP would pull out of the Executive if the IRA had not disbanded by January 18. The move came as a surprise to the Irish officials who, along with their UK counterparts, did not see the deadline as realistic. Sinn Fein described the resolution as a “wreckers’ charter”. Doubts were raised that there would be any progress on substantive issues as parties would not be engaged in “pre-election skirmishing”. As that could lead to a UUP walkout and the resulting suspension of the institutions, the prospect of delaying the elections was raised while bringing forward the vote was ruled out. Therefore, the two Governments stressed the need to cooperate as a stabilising force to protect the Agreement – despite not being sure how that process would survive through the January 18 deadline. The Irish officials became worried that the British side did not share their view that Mr Trimble was not “salvageable” and that the fundamental dynamic in the UUP was now Agreement scepticism, the confidential documents state. In a meeting days after the UUC announcements, Mr Reid is recorded in the documents as saying that as infuriating as it was, Mr Trimble was at that moment the “most enlightened Unionist we have”. The Secretary said he would explore what the UUP leader needed to “survive” the period between January 18 and the election, believing a significant prize could avoid him being “massacred”. Such planning went out the window just weeks later, when hundreds of PSNI officers were involved in raids of several buildings – including Sinn Fein’s offices in Stormont. The resulting “Stormontgate” spy-ring scandal accelerated the collapse of powersharing, with the UUP pulling out of the institutions – and the Secretary of State suspending the Assembly and Executive on October 14. For his part, Irish officials were briefed that Mr Reid was said to be “gung ho” about the prospect of exercising direct rule – reportedly making no mention of the Irish Government in a meeting with Mr Trimble and Mr Durkan on that day. The Northern Ireland Secretary was given a new role and Paul Murphy was appointed as his successor. A note on speaking points for a meeting with Mr Murphy in April showed that the Irish side believed the May elections should go ahead: “At a certain stage the political process has to stand on its own feet. “The Governments cannot be manipulating and finessing every scenario to engineer the right result. “We have to start treating the parties and the people as mature and trusting that they have the discernment to make the right choices.” However, the elections planned for May did not materialise, instead delayed until November. Mr Trimble would go on to lose his Westminster seat – and stewardship of the UUP – in 2005. The November election saw the DUP emerge as the largest parties – but direct rule continued as Ian Paisley’s refused to share power with Sinn Fein, which Martin McGuinness’ colleagues. The parties eventually agreed to work together following further elections in 2007. – This article is based on documents in 2024/130/5, 2024/130/6, 2024/130/15
In conclusion, while the fire at the Alibaba data center may have sparked concern, the swift and transparent response from the company helped to reassure users that their cloud services were not impacted. This incident underscores the importance of robust safety measures and emergency preparedness in the tech industry, emphasizing the need for continuous vigilance to safeguard critical data infrastructure. Moving forward, it is crucial for cloud providers to learn from such incidents and strengthen their disaster response capabilities to ensure uninterrupted service delivery to their customers.
This ambitious move by Amazon aims to cater to the increasingly fast-paced lifestyle of Indian consumers who value efficiency and convenience. With the convenience of ordering online becoming more popular, the demand for rapid delivery has grown significantly. Amazon's decision to offer a 15-minute delivery service underscores its commitment to meeting the evolving needs of its customers.
This ambitious move by Amazon aims to cater to the increasingly fast-paced lifestyle of Indian consumers who value efficiency and convenience. With the convenience of ordering online becoming more popular, the demand for rapid delivery has grown significantly. Amazon's decision to offer a 15-minute delivery service underscores its commitment to meeting the evolving needs of its customers.SACRAMENTO, Calif. (AP) — Marquel Sutton scored 23 points as Omaha beat Sacramento State 70-60 on Saturday night. Sutton added eight rebounds for the Mavericks (4-7). Tony Osburn scored 15 points and added five rebounds and three steals. JJ White had nine points and went 4 of 5 from the field. Jacob Holt led the way for the Hornets (2-7) with 15 points, six rebounds and two blocks. Mike Wilson added nine points and six rebounds for Sacramento State. Chudi Dioramma had seven points, 10 rebounds and two blocks. Omaha's next game is Friday against Northern Iowa on the road, and Sacramento State hosts UC Davis on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .CLASS ACTION NOTICE: Berger Montague Advises Evolv Technologies (NASDAQ: EVLV) Investors to ...The resilience demonstrated by Alibaba in responding to the data center fire underscores the company's dedication to maintaining the trust and confidence of its users and stakeholders. By swiftly addressing the crisis, communicating openly with the public, and prioritizing the safety of its employees and partners, Alibaba has set a positive example of crisis management in the face of adversity.
MELBOURNE, Australia and INDIANAPOLIS , Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr- girentuximab) kidney cancer imaging[2]. TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise. The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application. Kevin Richardson , Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC." About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada [8] . No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
Mellott throws 4 TD passes to lead top-seeded Montana State past UT Martin 49-17 in FCS playoffsMcLaughlin scores 23 as Northern Arizona knocks off South Dakota 95-82